SLC6A3 and Parkinson disease: Yearly DAT decline in PD patients has been estimated to be between 5 and 13% in striatal regions [31, 36, 37], meaning that [18F]FE-PE2I PET is well suited for measuring biological DAT differences in striatal regions in a longitudinal follow-up study with a typical sample size for PET studies.